Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2C(ser) and DRD3(gly) alleles to susceptibility

Psychopharmacology

Volumn 152, Issue 4, 2000, Pages 408-413

  Segman, R H ^a   Heresco Levy, U ^a   Finkel, B ^a   Inbar, R ^a   Neeman, T ^a   Schlafman, M ^a   Dorevitch, A ^a   Yakir, A ^a   Lerner, A ^a   Goltser, T ^a   Shelevoy, A ^a   Lerer, B ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Complex phenotype; Dopamine D3 receptor gene (DRD3); Genetic association; Pharmacogenetic; Schizophrenia; Serotonin 5 HT2C receptor gene (HT2CR); Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN 2C RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENDER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ALLELES; ANALYSIS OF VARIANCE; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 0033667902     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000521     Document Type: Article

References (27)

1. Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera
2. 'Tardive' dyskinesia: Etiological and therapeutic aspects
3. The dopamine transporter: Potential involvement in neuropsychiatric disorders
4. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
5. The effect of haloperidol feeding on dopamine receptor number in ten mouse strains
6. Tardive akathisia: An analysis of clinical features and response to open therapeutic trials
7. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia
8. A role for the subthalamic nucleus in the 5-HT2C induced oral dyskinesia
9. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
10. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979
11. Positive and negative syndrome scale (PANSS) rating manual
12. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C)
13. HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses
14. Homozygosity for Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients
15. The role of serotonin in antipsychotic drug action
16. Allelic variation in the 5-HT2C receptor and functional response to the 5-HT2c receptor antagonist mCPP
17. Dopamine D3 receptor variant and tardive dyskinesia
18. Possible genetic factors underlying the pathophysiology of tardive dyskinesia
19. Research diagnoses for tardive dyskinesia
20. 5-HT2C receptor gene polymorphism, schizophrenia and chronic hospitalisation
21. Genotypic association between the dopamine D3 receptor gene and tardive dyskinesia in chronic schizophrenia
22. A rating scale for extrapyramidal side effects
23. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
24. Tardive dyskinesia and ethnicity: Review of the literature
25. Familial occurrence of tardive dyskinesia
26. The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia: Evidence from functional studies on serotonin mediated phosphoinositide hydrolysis